PAR-26-001: Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations that Experience Health Disparities

PAR-26-001: Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations that Experience Health Disparities

PAR-26-001 is a NIH parent announcement (PA) for a programmatic stream of NIH-defined clinical trial projects under R01 format. It covers screening, brief intervention, and referral to treatment or prevention (SBIRT/P) for ATOD use and misuse, with explicit focus on adult populations that face health disparities.

The NOFO is useful if you are planning implementation and effectiveness work that reaches real-world systems where patients and community members face uneven access to treatment, prevention, and follow-up support. Unlike many grants that only fund an intervention concept, this mechanism is designed for trial-capable, outcome-oriented studies with practical pathways to care.

Key details

Why this announcement is different from generic SBIRT opportunities

Many funding calls mention screening and brief intervention, but PAR-26-001 is notable for two things:

1. It requires an NIH-defined clinical trial structure, which changes application architecture.
2. It ties implementation and referral systems to adult populations identified in a disparity context.

That combination is unusual because it demands both scientific rigor and practical system integration. In other words, NIH is looking for applications that move beyond an educational module or app and actually improve whether adults are screened, briefed, referred, and linked to follow-up care.

Practical fit in the 2026/2027 planning window

The NOFO has a 2027 expiration, and the page includes recurring submission milestones across the NIH cycle, so this is not a one-time-only posting. It remains practical for teams that want to apply in either preparation year 2026 or early 2027, provided registrations, protocol design, and compliance readiness are in place.

Because this is a recurring-style NOFO, teams generally have three planning pathways:

• apply early in a near cycle if their protocol is ready;
• prepare for a later cycle to improve statistical design and implementation fidelity;
• and build a reusable protocol stack for future due dates.

A key operational implication is that you should treat this as a continuing grant pipeline item, not a one-off outreach campaign.

What NIH is actually evaluating

You can break NIH’s expectations into two layers.

Core scientific layer

The peer-review logic prioritizes:

• significance for the target population and care pathway,
• rigor of intervention and implementation design,
• feasibility of execution in settings with real-world constraints,
• and quality of workforce and institutional support.

Operational layer

Because this is a clinical-trial requirement, NIH reviewers and grants management focus on:

• whether study conduct can be carried out in nonideal clinical and community environments,
• participant flow from screening to referral,
• data integrity across sites,
• and whether follow-up plans are realistic for underserved or dispersed adult populations.

A high-scoring submission tends to show both a strong trial question and a credible system-level execution plan.

Eligibility and boundary conditions

The NOFO includes an expansive eligibility list for organizations and applicants in the U.S. In practical terms:

• Higher-education institutions and many nonprofit organizations can apply.
• For-profit and governmental entities can be eligible in defined formats.
• Health systems, community organizations, and certain public programs can be included depending on their role and compliance posture.

Two boundaries deserve special emphasis:

1. Foreign entities are not eligible as the main applicant.
2. Clinical trial architecture is required.

Because these are explicit architecture rules in this NOFO, teams should resolve them before writing long-form aims.

Project type and budget strategy

The NOFO describes an up-to-one 5-year project period and does not enforce a single flat award cap in the public summary. This means you are evaluated on fit and feasibility as much as on budget sophistication.

Practical budget guidance for this parent announcement:

• Use budget tables to mirror actual trial milestones.
• Align personnel lines with trial tasks (screening coordinators, analyst time, recruitment support, referral tracking).
• Include explicit costs for partner implementation support where the intervention requires workflow redesign.
• Avoid inflated budget line items that do not map to measurable milestones.

Because review committees inspect feasibility, your budget can hurt you if it is internally inconsistent with your method section.

Who should apply versus who should not

Strong fit

Apply if your team has:

• a clearly defined adult target population with measurable ATOD-related disparity barriers,
• a clinically meaningful trial protocol under R01/NIH definitions,
• partner organizations prepared to provide real referral and follow-up integration,
• internal infrastructure for human subject and clinical-trial compliance.

Weak fit

Skip this opportunity if you have only:

• an observational pilot without trial design,
• a purely descriptive service program with no NIH-defined clinical trial plan,
• minimal implementation pathway across settings,
• no ability to show continuity from screening to treatment/prevention referral.

Because PAR-26-001 requires NIH-style trial compliance, weak designs are usually nonresponsive, regardless of topic relevance.

Submission architecture

Submission is electronic. The NOFO points teams to NIH pathways that include:

• NIH ASSIST,
• institutional system-to-system (S2S),
• Grants.gov Workspace.

Regardless of route, the proposal has to be complete at the chosen due-date cutoff and comply with NIH eRA registration status.

A reliable workflow is:

• complete SAM/UEI and institutional registrations first,
• submit PI and grants office profile checks early,
• lock the SF424 package before your internal QA cycle,
• run a pre-submission check in the chosen system.

Application blueprint for this NOFO

The blueprint below is designed for teams with a single strong proposal:

Step 1: Scope lock

Write one page describing:

• what disparity gap you are addressing,
• why SBIRT/P mechanism is the right level of intervention,
• how participants move through screening, brief intervention, referral, and follow-up.

Step 2: Trial design lock

• define arms, comparator approach, and primary clinical or process outcomes,
• define success metrics in each stage of the pathway,
• include retention and referral verification methods,
• clarify data integrity plan for each site.

Step 3: Organizational lock

• draft collaboration letters for clinical and community partners,
• define roles for PI, co-investigators, statisticians, and site leads,
• confirm local capacity for participant identification and referral tracking.

Step 4: Compliance lock

• include clinical trial and human-subjects documentation aligned with NIH expectations,
• ensure budget and effort statements match narrative responsibilities,
• verify no missing registration required by eRA.

Step 5: Submission lock

• package attachments and required forms,
• run internal pre-submission checks,
• submit before system deadline to allow correction window.

Common reasons applications stall

The following issues repeatedly reduce competitiveness:

1. Eligibility mismatch: non-clinical designs in a clinical-trial-required opportunity.
2. Referral weakness: no realistic referral and continuation pathway after screening.
3. Underbuilt implementation: intervention is strong on paper, weak in delivery setting.
4. Timeline collapse: unrealistic recruitment and follow-up assumptions.
5. Registration lag: unresolved eRA registration or institutional profile issues.
6. Inconsistent budget narrative: effort and budget not tied to milestones.

If you see one of these at concept review, fix it before final assembly.

2026/2027 operational timeline template

Use this timeline backward from deadline:

• T-16 to T-12 weeks: finalize protocol and close trial endpoints.
• T-12 to T-8 weeks: secure organizational commitment letters and refine budget.
• T-8 to T-4 weeks: complete eRA registrations and upload core sections.
• T-4 to T-1 weeks: run compliance checks, internal review, and pre-submission dry run.
• T-1 to T: final submission and correction window.

This timeline is defensive and assumes heavy partner coordination. If your proposal is still waiting on partner agreements at T-8 weeks, consider shifting to the next cycle.

Official resources that should be consulted directly

• NOFO page (official announcement): https://grants.nih.gov/grants/guide/pa-files/PAR-26-001.html
• NIH grants application guide: https://grants.nih.gov/grants/how-to-apply-application-guide
• eRA Commons: https://public.era.nih.gov/
• Grants.gov Workspace: https://www.grants.gov
• eRA Service Desk for filing help: https://www.era.nih.gov/need-help/

FAQ

Is this announcement open or expired?

The source listing shows recurring timing and an expiration date in the 2027 period. For practical use, treat it as active for 2026/2027 planning while staying within current cycle rules.

Can we apply with a prevention-only protocol?

Yes, if the protocol remains within SBIRT/P and is structured as an NIH-defined clinical trial with proper adult disparity context.

Can foreign teams lead this NOFO?

No. Foreign organizations are not eligible directly. Non-domestic components can participate only as part of eligible U.S. applicant structures.

Is this only for treatment or can referral-to-prevention be included?

The NOFO explicitly includes prevention pathways in the SBIRT/P scope for adult ATOD use and misuse contexts.

Can one institution submit more than one application?

The NOFO allows multiple submissions where proposals are scientifically distinct and comply with non-overlap standards. Do not submit near-duplicate clinical designs in the same opportunity without clear distinctions.

Bottom line

PAR-26-001 is strongest for teams that already operate in a trial mindset and can prove real-world translation from screening to treatment-prevention linkage. It is not primarily a concept funder; it is an implementation-and-trial execution funder under an NIH-defined framework.

If your team can show measurable pathway design, implementation resilience, and strong partner support, this opportunity can support a practical 2026/2027 NIH application. If your proposal is still at a pilot service-planning stage, use the NOFO timeline template to build toward the next cycle rather than forcing an underprepared submission.